Nigeria’s Indigenous Treatments for Sleeping Sickness and River Blindness Reach 70% Development Milestone

By Simpson Global Media News Desk

Event: Progress update on indigenous medicine research and development
Theme: Local pharmaceutical research, nanotechnology and neglected tropical diseases
Date: Saturday, 7 November 2026
Time: Not publicly specified
Venue: Lagos, Nigeria
Organiser: Nigeria Natural Medicine Development Agency (NNMDA), in collaboration with the Nigerian Institute for Trypanosomiasis Research (NITR)

Research project reaches 70 per cent completion

Nigeria's effort to develop locally formulated treatments for sleeping sickness and river blindness has reached an estimated 70 per cent completion, according to the Director-General of the Nigeria Natural Medicine Development Agency (NNMDA), Professor Martins Emeje.

Emeje disclosed the progress in an interview with the News Agency of Nigeria (NAN) in Lagos on Saturday, 7 November 2026.

The project is being undertaken in collaboration with the Nigerian Institute for Trypanosomiasis Research (NITR), with the aim of developing natural medicine formulations for two neglected tropical diseases that continue to affect vulnerable populations.

The partnership is applying nanoscience and nanotechnology alongside pharmaceutical research to develop suitable dosage forms from natural medicinal materials.

Emeje said the initial 12-month timeline could not be achieved because of funding shortages, logistical difficulties and delays in obtaining essential project inputs.

He expressed optimism that the work could progress towards completion, with stability studies expected to take place over the next six months.

However, the reported 70 per cent completion refers to the research and development project. It does not mean that the proposed treatments have completed clinical trials, received regulatory approval or become available for public use.

Two neglected tropical diseases targeted

The research focuses on African trypanosomiasis, commonly known as sleeping sickness, and onchocerciasis, widely called river blindness.

Both diseases are classified as neglected tropical diseases because they disproportionately affect populations in vulnerable communities, particularly in areas where access to healthcare, diagnosis and treatment can be limited.

Sleeping sickness is caused by parasites transmitted through the bites of infected tsetse flies.

The disease affects the central nervous system and can cause symptoms such as fever, headaches, fatigue and sleep disturbances. In advanced stages, it can disrupt normal sleep patterns and cause neurological complications.

Without appropriate diagnosis and treatment, the infection can become life-threatening.

River blindness is caused by the parasitic worm Onchocerca volvulus, which is transmitted through repeated bites from infected blackflies that breed near fast-flowing rivers.

The disease can cause severe itching, skin changes and visual impairment, including permanent blindness in advanced cases.

Both conditions require effective public-health interventions, including disease surveillance, prevention, diagnosis and access to appropriate treatment.

How the Nigerian research partnership works

The NNMDA and NITR collaboration was formalised through a memorandum of understanding signed in January 2026.

The agreement brought together the research and technical capabilities of the two institutions to develop locally sourced solutions for the targeted diseases.

According to Emeje, NITR contributes expertise in epidemiology, disease pathophysiology and clinical animal studies relating to trypanosomiasis and onchocerciasis.

The institute also provides research knowledge concerning the diseases and their vectors.

NNMDA contributes pharmaceutical research and nanomedicine capabilities, including work on converting medicinal materials into suitable dosage forms.

The agencies said the arrangement was designed to combine their complementary areas of expertise and reduce institutional barriers that can slow the development of locally researched health products.

The use of nanoscience and nanotechnology is intended to support the formulation process. However, the effectiveness and safety of any resulting medicine must still be established through appropriate scientific and regulatory procedures.

Funding and logistical difficulties delay the project

Emeje said the original 12-month development schedule could not be achieved because the project experienced funding and logistical challenges.

The disclosure highlights the difficulties facing publicly supported research institutions seeking to move scientific discoveries towards usable medical products.

Research and development require funding for laboratory equipment, qualified personnel, raw materials, testing, documentation and other essential activities.

The development of a medicine also involves several stages, including formulation, stability assessment, preclinical evaluation and clinical trials where required.

Delays in obtaining the necessary resources can affect the timing of these stages and postpone the eventual availability of a product.

Emeje said the agencies remained committed to completing the work, with stability studies expected over the next six months.

Stability studies are used to assess how a product's quality changes under specified storage conditions over time. They help determine factors such as shelf life, storage requirements and the period during which a formulation is expected to remain within acceptable quality limits.

The studies are an important part of pharmaceutical development, but completing them does not by itself establish that a medicine is safe and effective for human use.

Forty-seven other natural medicine products under development

Beyond the sleeping sickness and river blindness project, Emeje disclosed that NNMDA had 47 natural medicine products at advanced stages of preclinical development.

He said the products were being developed for a range of health conditions, including malaria, hypertension, hepatitis, diabetes, glaucoma, sickle cell disease, erectile dysfunction and peptic ulcer disease.

According to the agency's director-general, the products had reached a stage where they were ready for clinical trials, but insufficient funding was delaying their progression.

He estimated that clinical trials for one product could cost approximately ₦1.6 billion.

The amount illustrates the financial demands associated with moving potential treatments from laboratory research into the stages required to establish their safety and effectiveness in humans.

If applied to all 47 products, the potential cost would be substantial, although the agency has not announced a single consolidated financing requirement covering every product.

The disclosure also highlights the importance of deciding which research candidates should receive priority based on scientific evidence, public-health needs, safety considerations and available resources.

Twenty-two product applications submitted to NAFDAC

Emeje also disclosed that 22 applications relating to the agency's products had been submitted to the National Agency for Food and Drug Administration and Control (NAFDAC).

He clarified that the six natural medicine products unveiled by the Minister of Innovation, Science and Technology in July 2026 had undergone scientific evaluation and had preclinical dossiers prepared.

However, he said those products had not entered full commercial production.

The distinction is important because the submission of an application to a regulatory authority does not automatically mean that a product has been approved.

Regulatory assessment involves reviewing the evidence provided by applicants and determining whether the product meets the relevant requirements.

Depending on the product and its intended use, further information, testing or clinical evidence may be required.

Emeje stressed that scientific validation and regulatory approval are separate stages of drug development.

Consequently, Nigerians should not interpret the announcement as confirmation that the 47 research products or the proposed sleeping sickness and river blindness treatments are already approved medicines.

Call for private-sector investment in research

The NNMDA director-general called for stronger participation by private pharmaceutical companies in the development and commercialisation of locally researched medicines.

He said the agency had begun discussions with pharmaceutical companies and other industry stakeholders to explore partnerships that could support clinical trials, regulatory processes and eventual commercial production.

Emeje argued that public research institutions could benefit from private-sector capital, manufacturing capacity and commercial expertise.

He cited the partnership between Oxford University and pharmaceutical company AstraZeneca in the development of the COVID-19 vaccine as an example of how research institutions and commercial organisations can work together.

Such partnerships can provide funding and technical support that public institutions may struggle to secure independently.

For Nigeria, stronger cooperation between universities, research agencies, pharmaceutical manufacturers and investors could help reduce the distance between scientific discoveries and products that reach patients.

However, commercial partnerships must also protect research integrity, patient safety, intellectual property and the public interest.

Importance of scientific validation and patient safety

The development of medicines from natural materials requires careful scientific evaluation.

The fact that a substance comes from a plant or other natural source does not automatically establish that it is safe, effective or suitable for treating a particular disease.

Natural materials can contain active compounds that have beneficial effects, but they can also contain substances capable of causing adverse reactions.

The concentration of active ingredients may vary depending on the source, preparation method, storage conditions and manufacturing process.

For this reason, pharmaceutical development requires consistent formulation, quality control, safety evaluation and evidence of effectiveness.

Emeje said the agency's research products undergo scientific evaluation and that safety assessment remains central to its work.

He also distinguished scientifically researched natural medicines from unregulated herbal preparations sold by unqualified practitioners.

The distinction is important in a market where consumers may encounter products making medical claims without adequate evidence or regulatory oversight.

Traditional medicine registry planned

Emeje also disclosed that NNMDA was developing a national digital registry of traditional medicine practitioners, their products and treatment facilities.

He said the initiative was intended to improve documentation, accountability and research into indigenous medical knowledge.

According to him, the registry project began approximately three years ago and had covered two local government areas, with plans to expand it across all 774 local government areas in Nigeria.

The proposed registry could provide a structured record of practitioners, products and facilities involved in traditional medicine.

Such documentation may help researchers identify areas requiring further investigation and improve the availability of information about indigenous medical practices.

It could also support efforts to distinguish documented and scientifically evaluated products from unverified preparations.

However, the planned nationwide coverage remains an objective rather than a completed achievement.

Why neglected tropical diseases need attention

Sleeping sickness and river blindness are among the diseases that have historically received less international research investment than some other major infectious diseases.

They can affect communities where healthcare services are difficult to access and where poverty, geographical isolation and limited public-health infrastructure complicate prevention and treatment.

The diseases also have wider social and economic consequences.

People affected by chronic illness may experience difficulties maintaining employment, attending school or carrying out daily activities.

Visual impairment caused by river blindness can affect independence and household income, while advanced sleeping sickness can produce serious neurological complications.

Efforts to develop suitable treatments therefore form part of a wider public-health responsibility involving research, prevention, diagnosis, community awareness and access to healthcare.

Nigeria's proposed indigenous formulations could contribute to the country's research capacity if they eventually demonstrate acceptable safety and effectiveness.

Nevertheless, the success of the project will need to be measured through scientific evidence and regulatory outcomes, rather than development milestones alone.

What happens next?

The immediate next stage for the NNMDA and NITR project is to continue the formulation work and undertake the planned stability studies.

The agencies will also need to address the funding and logistical challenges that affected the original timetable.

If the research progresses successfully, the next steps will involve the relevant scientific evaluations and regulatory requirements before any proposed treatment can be considered for wider medical use.

For the agency's other 47 products, securing funding for clinical trials remains a major challenge.

The proposed partnerships with pharmaceutical companies could help provide the resources needed to advance selected candidates, although no completed financing agreement for all 47 products has been announced.

The 22 applications submitted to NAFDAC will also need to progress through the applicable regulatory processes.

A test for Nigeria's local medical research capacity

The latest disclosure highlights both the potential and the difficulties of developing medicines through Nigeria's own research institutions.

The NNMDA and NITR partnership demonstrates an effort to combine local scientific expertise, natural resources and pharmaceutical research in addressing diseases affecting vulnerable populations.

It also shows that developing a medicine involves more than identifying a promising natural substance.

Funding, laboratory capacity, product formulation, safety testing, clinical trials, regulatory assessment and commercial manufacturing are all necessary parts of the process.

For Nigeria, the development of credible local treatments could strengthen research capacity and create opportunities for domestic pharmaceutical manufacturing.

But the proposed sleeping sickness and river blindness products must first pass the scientific and regulatory stages required before they can be recommended for patient use.

The 70 per cent milestone is an encouraging progress report from the agencies. The decisive measure will be whether the project produces treatments that are scientifically validated, safe, effective and accessible to the people who need them.